CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00285-06v1
14/2/150    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bertini, S.
Right arrow Articles by Straus, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertini, S.
Right arrow Articles by Straus, A. H.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, February 2007, p. 150-156, Vol. 14, No. 2
1071-412X/07/$08.00+0     doi:10.1128/CVI.00285-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Expression of Antibodies Directed to Paracoccidioides brasiliensis Glycosphingolipids during the Course of Paracoccidioidomycosis Treatment{triangledown}

Silvio Bertini,1 Arnaldo L. Colombo,2 Helio K. Takahashi,1 and Anita H. Straus1*

Department of Biochemistry,1 Department of Medicine, Universidade Federal de São Paulo/Escola Paulista de Medicina, Rua Botucatu 862, São Paulo, SP 04023-900, Brazil2

Received 8 August 2006/ Returned for modification 12 September 2006/ Accepted 16 November 2006

Paracoccidioidomycosis (PCM) is a granulomatous disease caused by the dimorphic fungus Paracoccidioides brasiliensis. The immunoglobulin classes and isotypes of antibodies directed to acidic glycosphingolipids (GSLs) and glucosylceramide of P. brasiliensis were determined by enzyme-linked immunosorbent assay of sera from 31 PCM patients. The reactivities of 38 serum samples were analyzed by considering the stage of treatment: before antifungal treatment (n = 10), during 1 to 4 months of treatment (T1-4; n = 9), during 5 to 12 months of treatment (T5-12; n = 9), and posttreatment (PT; n = 10). Sera from healthy subjects (n = 12) were used as controls. Only the GSL Pb-1 antigen, which presents the carbohydrate structure Galfß1-6(Man{alpha}1-3)Manß1, was reactive with the PCM patient sera. The PCM patient sera did not react with Pb-2, which lacks the Galf residue and which is considered the biosynthetic precursor of Pb-1, indicating that the Galf residue is essential for antibody reactivity. The Pb-1 glycolipid from nontreated patients elicited a primary immune response with immunoglobulin M (IgM) production and subsequent switching to IgG1 production. The IgG1 titer increased after the start of antifungal treatment (T1-4 group), and general decreases in the anti-Pb-1 antibody titers were observed after 5 months of treatment (T5-12 and PT groups). The Pb-1 antigen, an acidic GSL with terminal Galf residue, has potential application as an elicitor of the host immune response in patients with PCM.

* Corresponding author. Mailing address: Department of Biochemistry, Universidade Federal de São Paulo, Rua Botucatu, 862-Ed. J. L. Prado, 04023-900 São Paulo, São Paulo, Brazil. Phone: 55-11-5549-4122. Fax: 55-11-5579-2509. E-mail: straus.bioq{at}epm.br.

{triangledown} Published ahead of print on 29 November 2006.

Clinical and Vaccine Immunology, February 2007, p. 150-156, Vol. 14, No. 2
1071-412X/07/$08.00+0     doi:10.1128/CVI.00285-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.